J. Angelinia*, A. Millera, C. Martíneza, M.E. Garcíab, M.E. Rodrígueza, J. Martíneza
Objetivos: Analizar: 1) el perfil lipídico en personas con glucemia de ayunas alterada (GAA) y 2) su posible asociación con parámetros clínico-metabólicos.
Material y métodos: Se reclutaron 101 personas de ambos sexos asistentes a consultorios de la Carrera Universitaria de Medicina Interna UNLP, incluyéndose personas >15 años que firmaron consentimiento informado para participar en el estudio; se excluyeron aquellos tratados con fármacos que afectaran el metabolismo lipídico y con diabetes tipo 2. En ellos se registraron antecedentes personales, heredofamiliares, hábitos de vida y ocurrencia de eventos cardiovasculares previos, índice de masa corporal (IMC), circunferencia de cintura (CC) y tensión arterial. En muestras de sangre se determinó glucemia, HbA1c y perfil lipídico; en la mayoría se agregó insulinemia e índice HOMA-IR. La evaluación estadística incluyó ANOVA y test de Tukey, considerándose significativas diferencias con valor de p ≤0,05.
Resultados: 67,32% de los participantes presentaron glucemias ≤100 mg/dl (grupo control) y el 32,67% disglucemias compatibles con el estado de GAA. La edad promedio, el IMC y la CC, los valores de HbA1c, insulina y HOMA-IR al igual que el porcentaje de personas con hipertensión arterial fueron significativamente mayores en este último grupo. Los valores del perfil lipídico registrados fueron mayores en el grupo de GAA excepto el c-HDL en el que fueron menores.
Conclusión: La dislipemia presente en personas con GAA sería simultáneamente un marcador de ateroesclerosis obliterante y un promotor de la transición a DT2, por lo que requiere su
diagnóstico y tratamiento precoz.
Aims: To analyze: 1) the lipid profile in people with impaired fasting glucose (IFG) and 2) its potential association with clinical and metabolic parameters.
Materials and methods: 101 people were recruited from those attending the University of Internal Medicine UNLP clinic, including people of both sexes, >15 years who sign informed consent to participate in the study; those treated with drugs that affect lipid metabolism and with type 2 diabetes were excluded. In all of them had we recoded body mass index (BMI), abdominal circumference (AC) and blood pressure. Their personal history, inherited relatives, life habits and occurrence of cardiovascular events were also recorded. In their blood samples, blood glucose, HbA1c and lipid profile were measured as well as insulin and HOMA-IR index in most of them.
Statistical evaluation included ANOVA and Tukey’s test; significant differences were considered when their p value was ≤0.05.
Results: 67.32% of the participants presented glycemias ≤100 mg/dl (control group) and 32.67% values compatible with IFG status. Mean age, BMI and WC, HbA1c, insulin and HOMA-IR values, as well as the percentage of people with hypertension, were significantly higher in the latter group. The values of the lipid profile recorded were higher in the GAA group except the HDL-c in which they were lower.
Conclusion: Since the dyslipidemia present in people with IFG would simultaneously be a marker of atherosclerosis obliterans and a promoter of the transition to DT2, it requires its early diagnosis and treatment.